Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy

被引:7
作者
Chen, Miaomiao [1 ]
Wang, Siliang [1 ,2 ]
机构
[1] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang 110004, Peoples R China
[2] 36 Sanhao Rd, Shenyang 110004, Peoples R China
关键词
PD-1/PD-L1; JAK/STAT signalling pathway; Drug combinations; Immunotherapy resistance; TUMOR-ASSOCIATED MACROPHAGES; REGULATORY T-CELLS; JAK-STAT PATHWAY; PD-1; BLOCKADE; INTERFERON-GAMMA; CANCER-CELLS; INHIBITION; EXPRESSION; RESISTANCE; CARCINOMA;
D O I
10.1016/j.intimp.2024.111717
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Programmed cell death protein 1 (PD -1) binds to its ligand to help tumours evade the immune system and promote tumour progression. Although anti-PD-1/PD-L1 therapies show powerful effects in some patients, most patients are unable to benefit from this treatment due to treatment resistance. Therefore, it is important to overcome tumour resistance to PD-1/PD-L1 blockade. There is substantial evidence suggesting that the JAK/ STAT signalling pathway plays a significant role in PD-1/PD-L1 expression and anti-PD-1/PD-L1 treatment. Herein, we describe the effects of the JAK/STAT signalling pathway on PD-1/PD-L1. Subsequently, the relationship between molecular mutations in the JAK/STAT signalling pathway and immune resistance was analysed. Finally, the latest advancements in drugs targeting the JAK/STAT pathway combined with PD1/PD-L1 inhibitors are summarised.
引用
收藏
页数:7
相关论文
共 50 条
[41]   In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies [J].
Denis, Morgane ;
Grasselly, Chloe ;
Choffour, Pierre-Antoine ;
Wierinckx, Anne ;
Mathe, Doriane ;
Chettab, Kamel ;
Tourette, Anne ;
Talhi, Nolan ;
Bourguignon, Aurore ;
Birzele, Fabian ;
Kress, Elsa ;
Jordheim, Lars Petter ;
Klein, Christian ;
Matera, Eva-Laure ;
Dumontet, Charles .
CANCER IMMUNOLOGY RESEARCH, 2022, 10 (08) :1013-1027
[42]   Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma [J].
Patrinely, James R., Jr. ;
Baker, Laura X. ;
Davis, Elizabeth J. ;
Song, Haocan ;
Ye, Fei ;
Johnson, Douglas B. .
CANCER, 2020, 126 (15) :3448-3455
[43]   Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment [J].
Alkhemeiri, Nasrah ;
Eljack, Sahar ;
Saber-Ayad, Maha Mohamed .
CELLS, 2025, 14 (10)
[44]   Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy [J].
Kim, Kyung Hwan ;
Kim, Chang Gon ;
Shin, Eui-Cheol .
IMMUNE NETWORK, 2020, 20 (01)
[45]   DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy [J].
Choi, Seong Hee ;
Mani, Muralidharan ;
Kim, Jeonghwan ;
Cho, Wha Ja ;
Martin, Thomas F. J. ;
Kim, Jee Hyun ;
Chu, Hun Su ;
Jeong, Won Jin ;
Won, Young-Wook ;
Lee, Byung Ju ;
Ahn, Byungyong ;
Kim, Junil ;
Jeon, Do Yong ;
Park, Jeong Woo .
CELL DEATH DISCOVERY, 2024, 10 (01)
[46]   Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis [J].
Liu, Haoran ;
Ye, Tao ;
Yang, Xiaoqi ;
Lv, Peng ;
Wu, Xiaoliang ;
Zhou, Hui ;
Lu, Hongyan ;
Tang, Kun ;
Ye, Zhangqun .
DISEASE MARKERS, 2020, 2020
[47]   Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28 [J].
Zhang, Chaoxu ;
Fan, Yibo ;
Che, Xiaofang ;
Zhang, Min ;
Li, Zhi ;
Li, Ce ;
Wang, Shuo ;
Wen, Ti ;
Hou, Kezuo ;
Shao, Xinye ;
Liu, Yunpeng ;
Qu, Xiujuan .
FRONTIERS IN ONCOLOGY, 2020, 10
[48]   Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy [J].
Brogden, Kim A. ;
Parashar, Deepak ;
Hallier, Andrea R. ;
Braun, Terry ;
Qian, Fang ;
Rizvi, Naiyer A. ;
Bossler, Aaron D. ;
Milhem, Mohammed M. ;
Chan, Timothy A. ;
Abbasi, Taher ;
Vali, Shireen .
BMC CANCER, 2018, 18
[49]   Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence [J].
Qi, Yihang ;
Zhang, Lin ;
Wang, Zhongzhao ;
Kong, Xiangyi ;
Zhai, Jie ;
Fang, Yi ;
Wang, Jing .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[50]   The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer [J].
Peng, Zhi ;
Cheng, Siyuan ;
Kou, Yan ;
Wang, Ziqi ;
Jin, Rong ;
Hu, Han ;
Zhang, Xiaotian ;
Gong, Ji-fang ;
Li, Jian ;
Lu, Ming ;
Wang, Xicheng ;
Zhou, Jun ;
Lu, ZhiHao ;
Zhang, Quan ;
Tzeng, David T. W. ;
Bi, Dongtao ;
Tan, Yan ;
Shen, Lin .
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (10) :1251-1261